TLR2 and Parkinson disease: Similarly, the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in a murine model of Parkinson’s disease causes the formation of p-α-synuclein deposits and an increase in TLR2 expression in enteric Schwann cells, promoting the production of proinflammatory factors (IL-1β, TNF-α, and NLRP3) through the TLR2/MyD88/NF-κB pathway, and the recovery of intestinal activity was achieved using a TLR2 inhibitor [33,34].